Cite
Giuliani J, Bonetti A. Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?. Eur Urol. 2017;73(3):e74doi: 10.1016/j.eururo.2017.10.010.
Giuliani, J., & Bonetti, A. (2018). Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?. European urology, 73(3), e74. https://doi.org/10.1016/j.eururo.2017.10.010
Giuliani, Jacopo, and Bonetti, Andrea. "Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?." European urology vol. 73,3 (2018): e74. doi: https://doi.org/10.1016/j.eururo.2017.10.010
Giuliani J, Bonetti A. Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?. Eur Urol. 2018 Mar;73(3):e74. doi: 10.1016/j.eururo.2017.10.010. Epub 2017 Oct 31. PMID: 29097098.
Copy
Download .nbib
